(VTRS) Viatris - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 15.031m USD | Total Return: 62.4% in 12m

Stock Prescription, Generic, Biosimilar, Complex, Injectables
Total Rating 59
Risk 54
Buy Signal 0.08
Drug Manufacturers - Specialty & Generic +0.7
Pharmaceuticals -0.1
Market Cap: 15,031m
Avg Trading Vol: 134M USD
ATR: 3.32%
Peers RS (IBD): 62.7
Risk 5d forecast
Volatility33.4%
Rel. Tail Risk-9.40%
Reward TTM
Sharpe Ratio1.45
Alpha47.55
Character TTM
Beta0.785
Beta Downside1.105
Drawdowns 3y
Max DD45.02%
CAGR/Max DD0.39
EPS (Earnings per Share) EPS (Earnings per Share) of VTRS over the last years for every Quarter: "2021-03": 0.92, "2021-06": 0.98, "2021-09": 0.99, "2021-12": 0.8, "2022-03": 0.93, "2022-06": 0.88, "2022-09": 0.87, "2022-12": 0.67, "2023-03": 0.77, "2023-06": 0.75, "2023-09": 0.79, "2023-12": 0.62, "2024-03": 0.67, "2024-06": 0.69, "2024-09": 0.75, "2024-12": 0.54, "2025-03": 0.5, "2025-06": 0.62, "2025-09": 0.67, "2025-12": 0.57,
EPS CAGR: -12.24%
EPS Trend: -79.3%
Last SUE: 0.86
Qual. Beats: 3
Revenue Revenue of VTRS over the last years for every Quarter: 2021-03: 4430.3, 2021-06: 4577.8, 2021-09: 4536.6, 2021-12: 4341.6, 2022-03: 4191.7, 2022-06: 4116.8, 2022-09: 4078.2, 2022-12: 3876, 2023-03: 3729.1, 2023-06: 3918.6, 2023-09: 3941.9, 2023-12: 3837.3, 2024-03: 3663.4, 2024-06: 3796.6, 2024-09: 3751.2, 2024-12: 3528.1, 2025-03: 3254.3, 2025-06: 3582.1, 2025-09: 3759.9, 2025-12: 3703.6,
Rev. CAGR: -3.25%
Rev. Trend: -75.5%
Last SUE: 2.22
Qual. Beats: 3
Description: VTRS Viatris

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company operating across four geographic segments-Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets-offering a broad portfolio that includes prescription brands, generics, complex generics, and biosimilars for therapeutic areas such as cardiovascular, CNS, oncology, and infectious diseases.

Recent data shows Viatris generated $13.2 billion in total revenue for FY 2023, with a 5.8 % year-over-year increase driven by strong generic drug demand in the United States and expanding biosimilar sales in Europe. The company’s R&D spend rose to $1.1 billion, reflecting a strategic focus on complex generics and next-generation biosimilars, while the global generic pharmaceuticals market is projected to grow at a CAGR of 7 % through 2028, supported by cost-containment pressures in major healthcare systems.

For deeper insights, consider reviewing ValueRay’s analyst coverage to complement your evaluation of Viatris’s growth prospects.

Headlines to Watch Out For
  • Generic drug competition erodes Viatriss established product revenue
  • Biosimilar pipeline approvals boost future sales growth
  • Debt reduction efforts improve financial stability
  • Regulatory scrutiny on drug pricing impacts profitability
  • Global economic slowdown reduces pharmaceutical demand
Piotroski VR‑10 (Strict) 5.0
Net Income: -3.51b TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.18 > 1.0
NWC/Revenue: 14.87% < 20% (prev 25.38%; Δ -10.51% < -1%)
CFO/TA 0.06 > 3% & CFO 2.32b > Net Income -3.51b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.30 > 1.5 & < 3
Outstanding Shares: last quarter (1.15b) vs 12m ago -3.41% < -2%
Gross Margin: 35.06% > 18% (prev 0.38%; Δ 3.47k% > 0.5%)
Asset Turnover: 36.34% > 50% (prev 35.52%; Δ 0.83% > 0%)
Interest Coverage Ratio: -6.78 > 6 (EBITDA TTM -395.4m / Interest Expense TTM 471.3m)
Altman Z'' -0.35
A: 0.06 (Total Current Assets 9.22b - Total Current Liabilities 7.09b) / Total Assets 37.19b
B: -0.01 (Retained Earnings -388.3m / Total Assets 37.19b)
C: -0.08 (EBIT TTM -3.19b / Avg Total Assets 39.35b)
D: -0.14 (Book Value of Equity -3.08b / Total Liabilities 22.48b)
Altman-Z'' Score: -0.35 = B
Beneish M -3.17
DSRI: 0.98 (Receivables 3.35b/3.52b, Revenue 14.30b/14.74b)
GMI: 1.09 (GM 35.06% / 38.15%)
AQI: 0.96 (AQ_t 0.67 / AQ_t-1 0.70)
SGI: 0.97 (Revenue 14.30b / 14.74b)
TATA: -0.16 (NI -3.51b - CFO 2.32b) / TA 37.19b)
Beneish M-Score: -3.17 (Cap -4..+1) = AA
What is the price of VTRS shares? As of April 03, 2026, the stock is trading at USD 13.51 with a total of 9,610,838 shares traded.
Over the past week, the price has changed by +0.52%, over one month by -13.66%, over three months by +8.79% and over the past year by +62.43%.
Is VTRS a buy, sell or hold? Viatris has received a consensus analysts rating of 3.44. Therefor, it is recommend to hold VTRS.
  • StrongBuy: 2
  • Buy: 1
  • Hold: 5
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the VTRS price?
Wallstreet Target Price 15.7 16.4%
Analysts Target Price 15.7 16.4%
VTRS Fundamental Data Overview as of 03 April 2026
P/E Forward = 5.3879
P/S = 1.0511
P/B = 1.0331
P/EG = 0.1436
Revenue TTM = 14.30b USD
EBIT TTM = -3.19b USD
EBITDA TTM = -395.4m USD
Long Term Debt = 12.48b USD (from longTermDebt, last quarter)
Short Term Debt = 2.04b USD (from shortTermDebt, last quarter)
Debt = 14.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.35b USD (from netDebt column, last quarter)
Enterprise Value = 28.28b USD (15.03b + Debt 14.70b - CCE 1.45b)
Interest Coverage Ratio = -6.78 (Ebit TTM -3.19b / Interest Expense TTM 471.3m)
EV/FCF = 15.53x (Enterprise Value 28.28b / FCF TTM 1.82b)
FCF Yield = 6.44% (FCF TTM 1.82b / Enterprise Value 28.28b)
FCF Margin = 12.73% (FCF TTM 1.82b / Revenue TTM 14.30b)
Net Margin = -24.58% (Net Income TTM -3.51b / Revenue TTM 14.30b)
Gross Margin = 35.06% ((Revenue TTM 14.30b - Cost of Revenue TTM 9.29b) / Revenue TTM)
Gross Margin QoQ = 30.63% (prev 36.83%)
Tobins Q-Ratio = 0.76 (Enterprise Value 28.28b / Total Assets 37.19b)
Interest Expense / Debt = 0.81% (Interest Expense 119.6m / Debt 14.70b)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.52b (EBIT -3.19b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.30 (Total Current Assets 9.22b / Total Current Liabilities 7.09b)
Debt / Equity = 1.00 (Debt 14.70b / totalStockholderEquity, last quarter 14.71b)
 Debt / EBITDA = -33.77 (negative EBITDA) (Net Debt 13.35b / EBITDA -395.4m)
 Debt / FCF = 7.34 (Net Debt 13.35b / FCF TTM 1.82b)
Total Stockholder Equity = 15.29b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.93% (Net Income -3.51b / Total Assets 37.19b)
RoE = -22.99% (Net Income TTM -3.51b / Total Stockholder Equity 15.29b)
RoCE = -11.50% (EBIT -3.19b / Capital Employed (Equity 15.29b + L.T.Debt 12.48b))
 RoIC = -8.51% (negative operating profit) (NOPAT -2.52b / Invested Capital 29.66b)
 WACC = 4.74% (E(15.03b)/V(29.73b) * Re(8.74%) + D(14.70b)/V(29.73b) * Rd(0.81%) * (1-Tc(0.21)))
Discount Rate = 8.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.50%
[DCF] Terminal Value 85.22% ; FCFF base≈1.87b ; Y1≈1.69b ; Y5≈1.45b
[DCF] Fair Price = 26.32 (EV 43.66b - Net Debt 13.35b = Equity 30.31b / Shares 1.15b; r=6.0% [WACC]; 5y FCF grow -12.37% → 3.0% )
EPS Correlation: -79.25 | EPS CAGR: -12.24% | SUE: 0.86 | # QB: 3
Revenue Correlation: -75.54 | Revenue CAGR: -3.25% | SUE: 2.22 | # QB: 3
EPS next Quarter (2026-06-30): EPS=0.60 | Chg7d=-0.005 | Chg30d=-0.044 | Revisions Net=-2 | Analysts=7
EPS current Year (2026-12-31): EPS=2.44 | Chg7d=-0.005 | Chg30d=-0.049 | Revisions Net=-2 | Growth EPS=+3.8% | Growth Revenue=+2.1%
EPS next Year (2027-12-31): EPS=2.66 | Chg7d=-0.005 | Chg30d=-0.083 | Revisions Net=-1 | Growth EPS=+8.8% | Growth Revenue=+1.8%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle